Table 2.
Demographic characteristics and outcomes of the target population in OneFlorida.
| Overall (N=2,531) | # of SAEs = 0 (N=2,034) | # of SAE > 0 (N=497) | ||||
| N (or Mean) | % (or SD) | N (or Mean) | % (or SD) | N (or Mean) | % (or SD) | |
| Age at last PX (years) | 59.09 | 11.4 | 59.46 | 11.4 | 57.59 | 11.29 |
| Gender | ||||||
| Female | 1,206 | 47.6% | 935 | 46.0% | 271 | 54.5% |
| Male | 1,325 | 52.4% | 1099 | 54.0% | 226 | 45.5% |
| Race/Ethnicity | ||||||
| Non-Hispanic White | 1,069 | 42.2% | 868 | 42.7% | 201 | 40.4% |
| Non-Hispanic Black | 481 | 19.0% | 377 | 18.5% | 104 | 20.9% |
| Hispanic | 528 | 20.9% | 407 | 20.0% | 121 | 24.3% |
| Other | 17 | 0.7% | 15 | 0.7% | 2 | 0.4% |
| Unknown | 436 | 17.2% | 367 | 18.0% | 69 | 13.9% |
| cPTG | 0.49 | 0.20 | 0.50 | 0.20 | 0.45 | 0.21 |
| Number of SAEs | 0.98 | 4.08 | 0 | 0 | 4.99 | 8.04 |
| Follow up days | 103.1 | 66.97 | 99.95 | 67.91 | 115.96 | 61.4 |
| Number of Bevacizumab PXs | 10.78 | 11.63 | 9.96 | 10.86 | 14.17 | 13.87 |
| First PX to Last PX in days | 263.52 | 328.17 | 234.75 | 296.8 | 381.21 | 413.49 |
*PX: Procedure; SAE: Serious Adverse Event; SD: Standard Deviation; cPTG: composite patient-trial generalizability